Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations

Journal of the National Cancer Institute

Volumn 105, Issue 3, 2013, Pages 237-243

  Haiman, Christopher A ^a   Stram, Daniel O ^a   Vickers, Andrew J ^b   Wilkens, Lynne R ^c   Braun, Katharina ^b,d   Valtonen André, Camilla ^e   Peltola, Mari ^f   Pettersson, Kim ^f   Waters, Kevin M ^a   Marchand, Loic Le ^c   Kolonel, Laurence N ^c   Henderson, Brian E ^a   Lilja, Hans ^b,e,g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF TURKU   (Finland)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNIC GROUP; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CALIFORNIA; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HAWAII; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873593387     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs486     Document Type: Article

References (27)

1. Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116-1121.
2. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-321.
3. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1122-1126.
4. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281-283.
5. Kote-Jarai Z, Olama AA, Giles GG, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785-791.
6. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3): 310-315.
7. Xu X, Valtonen-Andre C, Savblom C, et al. Polymorphisms at the microseminoprotein-beta locus associated with physiologic variation in betamicroseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2035-2042.
8. Waters KM, Stram DO, Le Marchand L, et al. A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2639-2646.
9. Nam RK, Reeves JR, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol. 2006;175(4): 1291-1297.
10. Whitaker HC, Kote-Jarai Z, Ross-Adams H, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010;5(10): e13363.
11. Whitaker HC, Warren AY, Eeles R, et al. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate. 2010;70(3):333-340.
12. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346-357.
13. Vaisanen V, Peltola MT, Lilja H, et al. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem. 2006;78(22):7809-7815.
14. Mitrunen K, Pettersson K, Piironen T, et al. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995;41(8 Pt 1): 1115-1120.
15. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011;7(5):e1001387.
16. Ulvsback M, Lindstrom C, Weiber H, et al. Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or betainhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun. 1989;164(3):1310-1315.
17. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987;214(2):317-322.
18. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate. 1988;12(1):29-38.
19. Reeves JR, Dulude H, Panchal C, et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res. 2006;12(20 Pt 1):6018-6022.
20. Bjartell AS, Al-Ahmadie H, Serio AM, et al. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007;13(14):4130-4138.
21. Abrahamsson PA, Lilja H, Falkmer S, et al. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 1988;12(1):39-46.
22. Shukeir N, Arakelian A, Kadhim S, et al. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res. 2003;63(9):2072-2078.
23. Beke L, Nuytten M, Van Eynde A, et al. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the polycomb group protein EZH2. Oncogene. 2007;26(31):4590-4595.
24. Udby L, Lundwall A, Johnsen AH, et al. beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun. 2005;333(2):555-561.
25. Guo M, Teng M, Niu L, et al. Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold. J Biol Chem. 2005;280(13):12405-12412.
26. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117(6):1210-1219.
27. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521.